Calamos Advisors LLC Decreases Position in Pfizer Inc. (NYSE:PFE)

Calamos Advisors LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,373,276 shares of the biopharmaceutical company’s stock after selling 11,354 shares during the quarter. Calamos Advisors LLC’s holdings in Pfizer were worth $39,537,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in PFE. Worth Asset Management LLC bought a new stake in Pfizer in the 1st quarter worth $29,000. Briaud Financial Planning Inc bought a new stake in Pfizer in the 3rd quarter worth $30,000. GoalVest Advisory LLC grew its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer during the 3rd quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PFE. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Stock Down 0.1 %

Pfizer stock traded down $0.04 during trading hours on Thursday, hitting $25.39. The stock had a trading volume of 35,629,531 shares, compared to its average volume of 42,480,207. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $143.74 billion, a P/E ratio of 70.25, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.56. The stock’s 50-day moving average price is $27.19 and its 200-day moving average price is $28.76.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.